About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Q2FY16 Call Transcript
  - Investor Presentation
  - Annual Reports
  Facilities Virtual Tour
  - Biocon Profile
  - CMD Profile
  - Video Gallery

          Patient Contact

          Patient Contact

for more details, please visit:

Write to:


At Biocon, we are driven by our passion to develop research - driven cutting edge therapies. Our tryst with innovation has enabled us to address the relatively unmet needs of our patients through differentiated products in challenging therapeutic spaces. We have earned the trust of patients and doctors through our products that are safe, efficacious and affordable. We are constantly engaged in pursuit of excellence to find solutions that heal the world.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company. We are committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer.

Through innovative products and research services we are constantly enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. We have successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.
Some of our key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody.

We have a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential oral insulin.

As the largest Indian Insulins Company, we believe we have made a huge difference to millions of diabetic patients in India. Over the years Biocon has also emerged as a leading Indian oncology company making cancer-care 'affordable' and 'accessible' to patients in India.





Highlights of Biocon Q2FY16
Stock Update

  Latest Press Release

Nov 13, 2015:
Biocon's Nationwide 'Winning with Diabetes' Campaign Raises Awareness on Disease Prevention & Management

  Media Coverage

Nov 04, 2015
Times of India:
Biocon only Asian co among top global biotech employers...

Oct 22, 2015
The Hindu:
Biocon PAT at Rs. 306 cr in Q2...


Biocon Foundation

Arogya Raksha Yojana

Biocon Malaysia



Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer | Authorised Users               © 2015, Biocon. All Rights Reserved